Oncology

Latest News

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

By Alana Hippensteele, MA

September 8th 2025

Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

By Alana Hippensteele, MA

September 7th 2025

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

By Alana Hippensteele, MA

September 7th 2025

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 9th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 9th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

March 15th 2017

Pembrolizumab Approved for Relapsed/Refractory Adult and Pediatric Hodgkin Lymphoma

Pembrolizumab (Keytruda) received an accelerated approval for adult and pediatric patients with refractory classical Hodgkin lymphoma or those who have relapsed after at least 3 lines of therapy.

March 15th 2017

Cancer Research Support Linked to Fewer Early Deaths, Hospitalizations

Christina Mattina

A new economic study has found that cancer types that were the focus of articles receiving public or private research support had fewer hospitalizations and lower mortality.

March 15th 2017

Syapse Looks to Expand Precision Medicine Partnerships With New CEO

Surabhi Dangi-Garimella, PhD

Ken Tarkoff, formerly at RelayHealth, is joining Syapse as its new CEO.

March 14th 2017

More Women With BRCA Mutations May Respond to PARP Inhibitors Than Previously Thought

Surabhi Dangi-Garimella, PhD

New research published in Nature Medicine has identified a broader population of individuals with breast cancer who can have therapeutic sensitivity to PARP inhibitors.

March 13th 2017

Ribociclib Approved as Front-Line Therapy for HR+/HER2- Breast Cancer

Laura Joszt, MA

The FDA has approved Novartis’ ribociclib (Kisqali) for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

March 13th 2017

Changes in Breast Density Following Hormone Therapy Predicts Cancer Risk

Surabhi Dangi-Garimella, PhD

A new study, published in the Journal of the National Cancer Institute, has confirmed that mammographic density change following estrogen and progestin treatment increases the risk of breast cancer.

March 13th 2017

Oncology Medical Homes, Patient Navigators Improved Quality and Saved Costs at End of Life

Christina Mattina

A recent study in Health Affairs assessed cost and utilization outcomes for 3 innovative care models for Medicare beneficiaries with cancer: oncology medical homes, patient navigator programs, and palliative care initiatives.

Dr Karen van Caulil Discusses Employers' Concerns About Rising Cancer Costs

March 13th 2017

Dr Karen van Caulil Discusses Employers' Concerns About Rising Cancer Costs

The cost of oncology care has increased significantly in recent years, leading employers to worry about how they can provide consistent benefits for employees with cancer and their family members, according to Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition.

Dr Carrie Stricker Explains How Her Clinical Experience Shapes Carevive's Work

March 11th 2017

Dr Carrie Stricker Explains How Her Clinical Experience Shapes Carevive's Work

Years of experience as an oncology nurse practitioner have underscored the importance of evidence-based resources for both patients and clinicians, says Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

Dr Stuart Goldberg: Patient Input and Data Analysis Are Keys to Value in Oncology

March 11th 2017

Dr Stuart Goldberg: Patient Input and Data Analysis Are Keys to Value in Oncology

When discussing value in oncology, the outcomes that matter are those that are important to the patient, said Stuart Goldberg, MD, chief medical officer, Cancer Outcomes Tracking and Analysis, John Theurer Cancer Center. He also discussed how the use of data to stratify patients is important for providing value-based cancer care.

March 10th 2017

Imatinib Safe and Effective on Long-Term Use in CML

Surabhi Dangi-Garimella, PhD

The selective BCR-ABL1 kinase inhibitor imatinib mesylate (Gleevec) has been found to be safe and effective following almost 11 years of follow-up in patients with chronic myeloid leukemia.

This Week in Managed Care: March 10, 2017

March 10th 2017

This Week in Managed Care: March 10, 2017

This week, the top managed care news included a bill from House Republicans to repeal and replace the Affordable Care Act, a new program at Walgreens to train pharmacists on an advanced cancer-care curriculum, and findings that health coaching helps the neediest patients most.

March 10th 2017

Patients Who Refuse Intervention for Thyroid Cancer at Risk of Disengaging From Care

Surabhi Dangi-Garimella, PhD

A study evaluating patients diagnosed with thyroid cancer who refused a clinical intervention for fear of being overdiagnosed has reported that the individuals feel isolated and anxious.

March 9th 2017

Slow Cancer Trial Accrual Rates Prevent Clinical Translation of Goals

Surabhi Dangi-Garimella, PhD

A new study from the MD Anderson Cancer Center has identified factors that influence cancer clinical trial accrual rates.

March 8th 2017

Exercise and Psychological Interventions Most Effective for Cancer-Related Fatigue

Christina Mattina

A review of research on the effectiveness of several treatments for cancer-related fatigue determined that exercise and psychological interventions resulted in more significant improvements than pharmaceutical regimens.

March 8th 2017

A Self-Persuasion App to Boost Adolescent HPV Vaccination Among Low-Income Families

Surabhi Dangi-Garimella, PhD

A pilot study conducted at a safety net hospital has armed researchers with a new educational tool: a digital app to persuade parents to vaccinate their adolescent against the human papilloma virus (HPV).

March 7th 2017

Study Compares Cost-Effectiveness of Immune Checkpoint Inhibitors in Advanced Melanoma

First-line pembrolizumab every 3 weeks followed by second-line ipilimumab, and first-line nivolumab followed by second-line ipilimumab are cost-effective strategies in patients with advanced melanoma expressing wild-type BRAF.

March 7th 2017

Walgreens Trains Staff, Identifies Cancer-Specialized Pharmacies

Surabhi Dangi-Garimella, PhD

Pharmacists and pharmacy technicians working at 50 specialty pharmacy locations owned by Walgreens have completed a cancer-focused curriculum of advanced education courses.

March 6th 2017

Remuneration for Gene Therapy Treatments: ICER Provides Early Recommendations

Surabhi Dangi-Garimella, PhD

How will drug developers price gene therapy treatments to recover their investment and ensure that society can bear the impending cost?

March 6th 2017

Part D Subsidies Can Help Reduce Racial Disparities in Breast Cancer Treatment Persistence

Christina Mattina

A recent study has found that low-income subsidies under the Medicare Part D program can help improve rates of persistence and adherence to breast cancer therapies among Hispanic and black women.

March 6th 2017

The Oncology Care Model: What to Expect in the First Data Feed

Eight months into the Oncology Care Model, find out what participants can expect from the first performance data feed released later this month.

March 5th 2017

Dana-Farber Clinical Pathways Saved Costs, Maintained Outcomes in NSCLC

Surabhi Dangi-Garimella, PhD

Implementation of clinical pathways saved $15,013 in the total cost of care per patient over a year.

Kim Eason Discusses How Payers Can Collaborate With Oncology Providers

March 5th 2017

Kim Eason Discusses How Payers Can Collaborate With Oncology Providers

Insurers can engage the practices they work with by building a sense of trust and open communication with the providers, according to Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ.

March 4th 2017

New Clinical Pathways Program Seamlessly Integrates Into Physician Workflow

A new clinical pathways program at the Cancer Treatment Centers of America will help inform treatment by seamlessly integrating into the physician’s electronic health record.

Melissa Thompson on Preparing Patients for the Reality of Cancer Treatment

March 3rd 2017

Melissa Thompson on Preparing Patients for the Reality of Cancer Treatment

Hospitals don't always adequately prepare patients for the reality of cancer treatment and all the ways it might affect someone's life, explained Melissa Thompson, MBA, healthcare strategist, patient, and self-advocate.

This Week in Managed Care: March 3, 2017

March 3rd 2017

This Week in Managed Care: March 3, 2017

This week, the top news in managed care included President Donald Trump's first address to Congress, which included guiding principles for replacing the Affordable Care Act, a leaked version of the House GOP's own draft for healthcare reform, and a study finds a concerning trend in colorectal cancer rates among young adults.

March 2nd 2017

Insurance Status, Race, and Education Remain Persistent Barriers to Cancer Screening

Surabhi Dangi-Garimella, PhD

While colorectal cancer screening rates have seen a recent progress toward achieving the Healthy People 2020 objectives, breast cancer screening rates have remained static, and cervical cancer screening rates have been declining.

March 2nd 2017

Juno's ROCKET Trial, Evaluating CAR-T Treatment in Leukemia Patients, Shelved

Surabhi Dangi-Garimella, PhD

The company did not recover from the 5 patient deaths associated with JCAR015 in 2016.

Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

March 1st 2017

Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Marcia Baker: Reducing Barriers to Medication Access and Adherence

March 1st 2017

Marcia Baker: Reducing Barriers to Medication Access and Adherence

Presentation by Marcia Baker, MS, Ed, director, Corporate Development & Programs, Mended Hearts, Inc, the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed CareÃ‚Â®.

...

82 83 84 85 86 87 88 89 90

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions